Servier’s Hungarian generic business Egis Pharmaceuticals acquired from AstraZeneca the rights for the anti-anemia prescription drug Sorbifer (ferrosii sulfas+ac.ascor). Egis has already been producing, distributing and promoting Sorbifer in 18 CEE and CIS markets since 1985 under a licence agreement with AstraZeneca. The product has become one of the major brands of Egis. According to the company, the current transaction is part of its growth and acquisition strategy in key markets.